221 related articles for article (PubMed ID: 2549421)
1. Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts.
Lombardi G; Gramegna G; Cavanna C; Poma G; Marangoni E; Michelone G
Mycopathologia; 1989 Apr; 106(1):31-4. PubMed ID: 2549421
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility of 245 yeast isolates to amphotericin B, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole.
Martín E; Parras P; Lozano MC
Chemotherapy; 1992; 38(5):335-9. PubMed ID: 1337508
[TBL] [Abstract][Full Text] [Related]
3. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses].
Uchida K; Matsuzaka A; Aoki K; Yamaguchi H
Jpn J Antibiot; 1991 May; 44(5):562-70. PubMed ID: 1652654
[TBL] [Abstract][Full Text] [Related]
4. Fluconazole vs amphotericin B: "in vitro" comparative evaluation of the minimal inhibitory concentration (MIC) against yeasts isolated from AIDS patients.
Lombardi G; Gramegna G; Cavanna C; Michelone G
Microbiologica; 1990 Jul; 13(3):201-6. PubMed ID: 2273982
[TBL] [Abstract][Full Text] [Related]
5. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.
Fromtling RA; Abruzzo GK; Bulmer GS
Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Morace G; Manzara S; Dettori G
Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
[TBL] [Abstract][Full Text] [Related]
7. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
[TBL] [Abstract][Full Text] [Related]
8. Flucytosine primary resistance in Candida species and Cryptococcus neoformans.
Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Rodríguez-Tudela JL
Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):276-9. PubMed ID: 11399020
[TBL] [Abstract][Full Text] [Related]
9. [In vitro susceptibility of Cryptococcus strains to 5 antifungal drugs].
Bava AJ; Negroni R
Rev Inst Med Trop Sao Paulo; 1989; 31(5):346-50. PubMed ID: 2560840
[TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
12. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test.
Linares MJ; Muñoz JF; Solís F; Rodríguez FC; Valero A; Casal M
Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparison of cilofungin alone and in combination with other antifungal agents against clinical isolates of Candida species.
Smith KR; Lank KM; Dismukes WE; Cobbs CG
Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):588-92. PubMed ID: 1655435
[TBL] [Abstract][Full Text] [Related]
14. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
15. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL
J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410
[TBL] [Abstract][Full Text] [Related]
16. Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans.
Davey KG; Holmes AD; Johnson EM; Szekely A; Warnock DW
J Clin Microbiol; 1998 Apr; 36(4):926-30. PubMed ID: 9542910
[TBL] [Abstract][Full Text] [Related]
17. Fluconazole, itraconazole and ketoconazole in-vitro activity. A comparative study.
Arzeni D; Barchiesi F; Ancarani F; Scalise G
J Chemother; 1991 Jun; 3(3):139-42. PubMed ID: 1655990
[TBL] [Abstract][Full Text] [Related]
18. Amphotericin B tolerance: a characteristic of Candida parapsilosis not shared by other Candida species.
Seidenfeld SM; Cooper BH; Smith JW; Luby JP; Mackowiak PA
J Infect Dis; 1983 Jan; 147(1):116-9. PubMed ID: 6822746
[TBL] [Abstract][Full Text] [Related]
19. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
20. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Silva PR; Rabelo RA; Terra AP; Teixeira DN
Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
